Comperative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 12, 2006, Pages 641-647

  Park, J Y ^a   Kim, K A ^a   Park, P W ^b   Lee, O J ^a   Kim, J S ^c   Lee, G H ^c   Ha, M C ^c   Park, J H ^c   O, M J ^c   Ryu, J H ^c  

^a Korea University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Hanlim Pharmaceutical Company Ltd   (South Korea)

Author keywords

Amlodipine; Bioavailability; Pharmacodynamics; Pharmacokinetics; Salt substitution

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE NICOTINATE; NAIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; NICOTINIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VOLUNTEER; ANALYSIS OF VARIANCE; BIOAVAILABILITY; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; HALF LIFE TIME; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHYSIOLOGY; TIME;

ADMINISTRATION, ORAL; ADULT; AMLODIPINE; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; HALF-LIFE; HEART RATE; HUMANS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; NIACIN; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 33845484063     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44641     Document Type: Article

References (20)

1. Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J. 1989; 118: 1100-1103.
2. Beresford AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA. Metabolism and kinetics of amlodipine in man. Xenobiotica. 1988; 18: 245-254.
3. Beresford AP, Macrae PV, Alker D, Kobylecki RJ. Biotransformation of amlodipine. Identification and synthesis of metabolites found in rat, dog and human urine/confirmation of structures by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Arzneimittelforschung. 1989; 39: 201-209.
4. Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci. 1977; 66: 1-19.
5. Carvalho M, Oliveira CH, Mendes GD, Sucupira M, Moraes ME, De Nucci G. Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm Drug Dispos. 2001; 22: 383-390.
6. Chow CS, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker; 1992.
7. Davies G. Changing the salt, changing the drug. Pharm J. 2001; 266: 322-323.
8. Farolfi M, Powers JD, Rescigno A. On the determination of bioequivalence. Pharmacol Res. 1999; 39: 1-4.
9. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986; 22: 21-25.
10. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Bernstsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991; 34: 1838-1844.
11. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995; 50: 560-586.
12. Josefsson M, Zackrisson AL, Ahlner J. Effect of grape-fruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol. 1996; 51: 189-193.
13. Meredith PA. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003; 25: 2875-2890.
14. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992; 22: 22-31.
15. Park JY, Kim KA, Lee GS, Park PW, Kim SL, Lee YS, Lee YW, Shin EK. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther. 2004; 26: 715-723.
16. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet. Biopharm. 1987; 15: 657-680.
17. Shargel L, Yu AB. Bioavailability and bioequivalence in applied biopharmaceutics and pharmacokinetics. New York: Appletons and Lange; 1999. pp. 247-279.
18. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol. 1988; 12 (Suppl 7): 55-59.
19. Verbeeck RK, Kanfer I, Walker RB. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci. 2006; 28: 1-6.
20. Walker DK, Humphrey MJ, Smith DA. Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica. 1994; 24: 243-250.